Licensing can help biotechnology companies share development costs and access a partner’s clinical, regulatory and commercial capabilities. The value to shareholders depends on the economics and the probability that the asset advances through trials and eventually reaches patients. Closing the deal does not remove …
Scancell Holdings PLC (LSE:SCLP) develops immunotherapies designed to help the immune system recognise and attack cancer. Its melanoma programme, broader pipeline and financing strategy provide reasons for cautious optimism. However, the apparent share-price surge requires adjustment for a corporate action before drawing conclusions about …
Thalia Therapeutics PLC (LSE:THAT) is being considered in the context of the FTSE AIM All-Share, where smaller listed businesses can react sharply to fresh disclosures, liquidity changes and shifts in risk appetite. The stock can still attract attention because investors are reassessing small-cap valuations, …
Tooru PLC (LSE:TOO) is being considered in the context of the FTSE AIM All-Share, where smaller listed businesses can react sharply to fresh disclosures, liquidity changes and shifts in risk appetite. The stock can still attract attention because investors are reassessing small-cap valuations, liquidity, …
Tristel plc (LSE:TSTL) is in focus for investors reviewing UK small-cap shares on 20 October 2026. The most useful way to assess the stock is to separate confirmed company information from broader sector themes, then identify which future milestones could materially change expectations. The …
Kooth PLC (LSE:KOO) is in focus for investors reviewing UK small-cap shares on 20 October 2026. The most useful way to assess the stock is to separate confirmed company information from broader sector themes, then identify which future milestones could materially change expectations. The …
CelLBxHealth plc (LSE:CLBX) is attracting attention on AIM on 20 October 2026 because its third quarter has just ended, and the company is under pressure to show that commercial momentum is building fast enough to secure its future. Investors want evidence of further pharma …
Cambridge Nutritional Sciences plc (LSE:CNSL) is on the radar of AIM healthcare investors on 20 October 2026 because its first half of FY27 has just ended. After a year in which geopolitical disruption hit headline revenue, investors want evidence that underlying growth can show …
Cambridge Cognition Holdings Plc (LSE:COG) is being considered in the context of the FTSE AIM All-Share, where smaller listed businesses can react sharply to fresh disclosures, liquidity changes and shifts in risk appetite. The latest available review suggests the following focus: Investors are likely …
CRISM Therapeutics Corporation (LSE:CRTX) is in focus for investors reviewing UK small-cap shares on 20 October 2026. The most useful way to assess the stock is to separate confirmed company information from broader sector themes, then identify which future milestones could materially change expectations. …